Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
GUTIERREZ CARLOS M reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Carlos M. Gutierrez received a grant of 721 shares of MetLife common stock on April 1, 2026. The shares were awarded at no cash cost as part of non-management director retainer fees paid in stock. Following this award, he directly holds 25,745 common shares and indirectly holds 18,807 additional shares through the Carlos M. Gutierrez Trust.
WEINBERGER MARK A reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Mark A. Weinberger received 721 shares of MetLife common stock as a grant tied to his non-management director retainer fees. The shares were awarded at no cash cost per share and increased his direct holdings to 18,801 shares of MetLife common stock.
Johnson Jeh C. reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Jeh C. Johnson received 721 shares of common stock as a compensation award. The grant was valued at $71.17 per share and increased his directly held position to 8,850 shares.
A footnote explains that a portion of non-management director retainer fees is paid in MetLife common stock, and Johnson elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This indicates the transaction is a routine equity-based board compensation event rather than an open-market purchase or sale.
MetLife submitted a Form 144 reporting proposed sales of Common Stock by affiliated accounts. The filing lists specific planned transactions and several sales completed in the prior three months, with per-transaction share counts and associated dollar amounts shown for accounts including MetLife 401k Plan Trust and Separate Account SPI.
MetLife Inc — The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting 0 shares and 0% beneficial ownership of MetLife common stock as of the amendment. The filing explains an internal realignment on January 12, 2026 that disaggregated certain subsidiaries' holdings from The Vanguard Group, Inc.
The report lists zero voting and dispositive power (sole and shared) for the filer and is signed by Ashley Grim on 03/27/2026.
MetLife reported insider sales of Common Stock. The excerpt lists dispositions of 562 shares on 01/09/2026 and 725 shares on 03/02/2026. The transactions are reported on a Form 144 covering Common Stock and reference NYSE trading.
MET filed a Rule 144 notice reporting sales of Common Stock.
The notice lists prior purchases and recent dispositions of Common Stock, including a 100-share purchase noted with 05/29/2015 (broker: GOLDMAN SACHS) and sales of 562 shares on 01/09/2026 and 725 shares on 03/02/2026. The filing identifies the NYSE and an entry date of 03/20/2026.
MetLife (MET) reported Form 144 notices for sales of Common Stock. The excerpt lists individual dispositions dated 01/09/2026 (562 shares) and 03/02/2026 (725 shares). The filings identify brokers and plan/ account names associated with the transactions.
MetLife reported proposed sales of Common Stock under Form 144. The filing lists a sale of 562 shares on 01/09/2026 with a value of $44,628.42 and a sale of 725 shares on 03/02/2026 with a value of $53,099. The securities are Common Stock traded on the NYSE; a broker address for Barclays is shown.
MetLife Inc. director Daniel S. Glaser reported an acquisition of 273 shares of common stock as a grant under non-management director compensation arrangements. The grant was valued at $75.34 per share, and he elected to defer receipt of these shares into the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this award, Glaser directly holds 1,380 common shares. The filing also notes 198 common shares held indirectly in a Grantor Retained Annuity Trust, which were previously reported as directly owned due to an administrative error and are now correctly classified as indirectly held.